Imac Holdings Inc (BACK)

$0.07 -0.13 (-64.50%)
Market Cap 887,000.00
Revenue (ttm) 0.00
Net Income (ttm) -9.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 859,700
Avg Vol 1,744,240
Day's Range N/A - N/A
Shares Out 2.07M
Stochastic %K 15%
Beta 0.16
Analysts Sell
Price Target $8.25

Company Profile

IMAC Holdings, Inc., through its subsidiary, Ignite Proteomics LLC, provides proteomic product and precision medicine services based on activated protein analysis for the treatment of cancer in the United States. The company offers a reverse phase protein array (RPPA) platform, which can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. IMAC Holdings, Inc. was founded in 2000 and is based in Franklin, Tennessee.

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 303 898 5896
Address:
3401 Mallory Lane, Suite 100, Franklin, United States
Latest News on BACK
Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers

Sep 10, 2025, 3:04 PM EDT - 11 months ago

Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers

IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery

Aug 7, 2025, 4:05 PM EDT - 1 year ago

IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

Feb 24, 2025, 8:15 AM EST - 1 year ago

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

Ignite Proteomics complete acquisition of PLA code 0249U

2025-02-19T14:20:31.000Z - 1 year ago

Ignite Proteomics complete acquisition of PLA code 0249U

Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

Feb 19, 2025, 9:15 AM EST - 1 year ago

Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

Feb 10, 2025, 9:15 AM EST - 1 year ago

Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies

Jan 27, 2025, 4:10 PM EST - 1 year ago

IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies

IMAC Holdings receives Nasdaq notification of deficiency

2024-11-22T22:20:29.000Z - 1 year ago

IMAC Holdings receives Nasdaq notification of deficiency

IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

Nov 22, 2024, 5:15 PM EST - 1 year ago

IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

IMAC Holdings granted extension by Nasdaq to regain compliance

2024-11-14T14:15:20.000Z - 1 year ago

IMAC Holdings granted extension by Nasdaq to regain compliance

IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)

Nov 14, 2024, 9:10 AM EST - 1 year ago

IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)

IMAC Holdings launches Ignite Proteomics subsidiary

2024-09-19T14:06:03.000Z - 2 years ago

IMAC Holdings launches Ignite Proteomics subsidiary

IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology

Sep 19, 2024, 10:00 AM EDT - 2 years ago

IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology

IMAC Holdings receives noncompliance notification from Nasdaq

2024-08-23T21:23:45.000Z - 2 years ago

IMAC Holdings receives noncompliance notification from Nasdaq

IMAC Holdings appoints Matthew Schwartz, Peter Beitsch to board

2024-07-11T13:22:45.000Z - 2 years ago

IMAC Holdings appoints Matthew Schwartz, Peter Beitsch to board

IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

Jul 11, 2024, 9:21 AM EDT - 2 years ago

IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

IMAC Holdings files to sell common stock, warrants, no amount given

2024-06-13T20:51:47.000Z - 2 years ago

IMAC Holdings files to sell common stock, warrants, no amount given

IMAC Holdings appoints Faith Zaslavsky as CEO

2024-05-24T13:05:05.000Z - 2 years ago

IMAC Holdings appoints Faith Zaslavsky as CEO

IMAC Holdings Announces Leadership Succession

May 24, 2024, 9:00 AM EDT - 2 years ago

IMAC Holdings Announces Leadership Succession

IMAC Holdings acquires assets of Theralink

2024-05-07T12:48:48.000Z - 2 years ago

IMAC Holdings acquires assets of Theralink

IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business

May 7, 2024, 8:30 AM EDT - 2 years ago

IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business

IMAC Holdings Inc trading resumes

2024-04-26T13:37:03.000Z - 2 years ago

IMAC Holdings Inc trading resumes

IMAC Holdings Inc trading halted, volatility trading pause

2024-04-26T13:32:04.000Z - 2 years ago

IMAC Holdings Inc trading halted, volatility trading pause

IMAC Holdings price target lowered to $10 from $34.50 at Ascendiant

2023-11-24T11:33:38.000Z - 2 years ago

IMAC Holdings price target lowered to $10 from $34.50 at Ascendiant

IMAC Holdings regains compliance with Nasdaq minimum bid price rule

2023-09-27T20:38:22.000Z - 3 years ago

IMAC Holdings regains compliance with Nasdaq minimum bid price rule

IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Sep 27, 2023, 4:30 PM EDT - 3 years ago

IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

IMAC Holdings announces 1-for-30 reverse stock split

2023-09-07T16:45:42.000Z - 3 years ago

IMAC Holdings announces 1-for-30 reverse stock split

IMAC Holdings, Inc. Announces 1-for-30 Reverse Stock Split

Sep 7, 2023, 12:45 PM EDT - 3 years ago

IMAC Holdings, Inc. Announces 1-for-30 Reverse Stock Split

IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market

Jul 26, 2023, 9:25 AM EDT - 3 years ago

IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market

IMAC Holdings Annual Meeting of Shareholders Reminder

Jun 28, 2023, 4:30 PM EDT - 3 years ago

IMAC Holdings Annual Meeting of Shareholders Reminder

Theralink appoints Faith Zaslavsky as CEO

2023-06-27T13:22:50.000Z - 3 years ago

Theralink appoints Faith Zaslavsky as CEO

THERALINK INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Theralink Technologies, Inc. - THER

May 30, 2023, 11:04 PM EDT - 3 years ago

THERALINK INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Theralink Technologies, Inc. - THER

Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company

May 23, 2023, 9:43 AM EDT - 3 years ago

Theralink® Signs Definitive Merger Agreement to be Acquired by IMAC Holdings, a Nasdaq Listed Company

IMAC Holdings Reports Year End 2022 Financial Results and Corporate Update

Mar 31, 2023, 8:00 PM EDT - 3 years ago

IMAC Holdings Reports Year End 2022 Financial Results and Corporate Update

IMAC Holdings, Brain Scientific announce strategic merger

2023-03-20T11:33:37.000Z - 3 years ago

IMAC Holdings, Brain Scientific announce strategic merger

IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution

Mar 20, 2023, 7:30 AM EDT - 3 years ago

IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution

IMAC Holdings, Inc announces the sale of The BackSpace

Mar 1, 2023, 9:30 AM EST - 3 years ago

IMAC Holdings, Inc announces the sale of The BackSpace

IMAC Holdings, Inc. Hosts Hall of Fame Athlete Panel at the Evoke Conference to Launch Whole Food Supplement Partnership

Oct 21, 2022, 10:30 AM EDT - 4 years ago

IMAC Holdings, Inc. Hosts Hall of Fame Athlete Panel at the Evoke Conference to Launch Whole Food Supplement Partnership

IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease

Sep 9, 2022, 9:22 AM EDT - 4 years ago

IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease

Biote Announces Strategic Partnership with IMAC Holdings, Inc.

Sep 7, 2022, 8:30 AM EDT - 4 years ago

Biote Announces Strategic Partnership with IMAC Holdings, Inc.

BTMD

IMAC Holdings, Inc. Announces Addition of Medical Weight Loss Services to IMAC Regeneration Centers

Sep 1, 2022, 9:44 AM EDT - 4 years ago

IMAC Holdings, Inc. Announces Addition of Medical Weight Loss Services to IMAC Regeneration Centers

IMAC Holdings, Inc. Announces Closing of $3.9 Million Registered Direct and Private Placement Offerings

Aug 16, 2022, 4:00 PM EDT - 4 years ago

IMAC Holdings, Inc. Announces Closing of $3.9 Million Registered Direct and Private Placement Offerings

IMAC Holdings Reports Record Revenue of $5M in Second Quarter

Aug 15, 2022, 11:30 AM EDT - 4 years ago

IMAC Holdings Reports Record Revenue of $5M in Second Quarter

IMAC Holdings, Inc. Announces $3.9 Million Registered Direct and Private Placement

Aug 12, 2022, 9:16 AM EDT - 4 years ago

IMAC Holdings, Inc. Announces $3.9 Million Registered Direct and Private Placement